Health information to help you understand symptoms. It isn't a diagnosis.
Check symptoms

Research deep dives

Diabetes medicines: how each one works

Last reviewed November 17, 2026. OwieClear editorial team. Waiting for clinician review. Not medical advice. Talk with your doctor about your own care.

There are now more than half a dozen classes of medicine for type 2 diabetes, and they do genuinely different things. Two of them reduce heart and kidney damage by routes that have little to do with blood sugar.

Knowing which class a tablet belongs to tells you most of what you need to know about what it does, what it costs you in side effects, and whether it can drop your blood sugar too low.

Related pages: Type 2 diabetes

The bottom line

What we know
  • Metformin remains the usual first medicine for most people.
  • GLP-1 receptor agonists and SGLT2 inhibitors reduce cardiovascular and kidney events beyond their glucose effect.
  • Metformin, GLP-1 agonists, SGLT2 inhibitors and DPP-4 inhibitors do not cause low blood sugar on their own.
  • Sulfonylureas and insulin can cause low blood sugar and need teaching about it.
  • Medicines should not be stopped because numbers improve, without discussing it first.
What is still open
  • How to sequence the newer classes for each individual.
  • Whether starting combination treatment immediately beats stepping up.
  • Long-term effects of the newest dual and triple agonists.

The story, step by step

  1. 1. Metformin ()
  2. 2. GLP-1 agonists ()
  3. 3. SGLT2 inhibitors ()
  4. 4. The older classes ()
  5. 5. Insulin ()
  6. 6. Choosing ()
What the evidence labels mean
GuidelineAn official recommendation from an expert group after weighing all the evidence.
Review of many studiesCombines the results of many studies (a systematic review or meta-analysis).
Randomized trialPeople were randomly given a treatment or a comparison, the best way to test cause and effect.
Large observational studyFollows many people over time. Shows strong links, but not always cause and effect.
Small or early studyA small study, case series, or first results. Needs to be confirmed.
Lab or animal studyDone in cells or animals. May not apply to people.
Part 1 of 6

The usual first step

Review of many studies

What happens

Reduces the liver's glucose output.

What the research shows

  • Metformin mainly reduces glucose production by the liver, and modestly improves insulin sensitivity in muscle.
  • It does not cause low blood sugar on its own, is weight-neutral or slightly weight-reducing, and is inexpensive.
  • The common side effects are gastrointestinal: nausea, loose stools, abdominal discomfort. Starting low, increasing slowly, taking it with food and using the extended-release form all help.
  • Long-term use can lower vitamin B12, and levels are worth checking periodically, particularly in anyone with numbness or tingling.
  • It is reduced or avoided in significant kidney impairment, and is usually paused around scans using contrast dye and during serious illness or dehydration.
  • Lactic acidosis is the serious but rare risk, essentially confined to situations where it should have been withheld.

Why it matters

Decades of use, low cost and a good safety record keep metformin first for most people, even as newer drugs outperform it on weight and organ protection.

What's still uncertain

  • Whether it should remain first-line for people with established heart or kidney disease.
  • How much of its cardiovascular benefit is real and how much is historical artefact.

Read more

Next: GLP-1 agonists

Part 2 of 6

Gut hormone, longer lasting

Review of many studies

What happens

Amplify insulin, suppress glucagon, reduce appetite.

What the research shows

  • These drugs mimic GLP-1, the gut hormone that amplifies insulin release after eating, suppresses glucagon and slows stomach emptying.
  • They act on appetite centres in the brain, producing substantial weight loss. The newer agents produce the largest weight reductions of any diabetes medicines.
  • Several have been shown in trials to reduce major cardiovascular events in people with type 2 diabetes and established heart disease or high risk.
  • They do not cause low blood sugar on their own, because their effect on insulin is glucose-dependent.
  • Nausea is the main side effect, usually early and dose-related. Slow dose escalation is the standard answer.
  • Most are weekly injections; an oral form exists. They are avoided in those with a personal or family history of medullary thyroid cancer or MEN2, and paused as advised before general anaesthesia because of delayed stomach emptying.

Why it matters

This class changed what treatment aims at: not just a lower number, but weight and cardiovascular risk at the same time.

What's still uncertain

  • How long the weight loss is maintained and what happens on stopping.
  • Effects on muscle mass with large weight reductions.

Read more

Next: SGLT2 inhibitors

Part 3 of 6

Glucose out through the urine

Review of many studies

What happens

Block reabsorption in the kidney.

What the research shows

  • The kidney normally filters glucose and reabsorbs essentially all of it. SGLT2 inhibitors block that reabsorption, so glucose leaves in the urine.
  • The glucose-lowering effect is modest, but the organ protection is not. These drugs reduce heart failure hospitalisation and slow progression of chronic kidney disease, including in people without diabetes.
  • They also reduce blood pressure slightly and produce modest weight loss.
  • They do not cause low blood sugar on their own.
  • Genital yeast infections are the common side effect; good hygiene reduces them. Urinary tract infections are somewhat more frequent.
  • Two rarer risks matter: euglycemic diabetic ketoacidosis, in which ketoacidosis occurs with near-normal blood sugar, and dehydration. The drugs are usually held during serious illness, prolonged fasting, very low carbohydrate intake and before surgery.

Why it matters

The kidney and heart failure benefits are large enough that these drugs are now prescribed for those reasons specifically, independent of what the A1C is doing.

What's still uncertain

  • Where exactly they belong in the sequence for people without heart or kidney disease.
  • How best to prevent the rare ketoacidosis cases.

Read more

Next: The older classes

Part 4 of 6

Sulfonylureas, DPP-4, pioglitazone

Review of many studies

What happens

Still useful, with known trade-offs.

What the research shows

  • Sulfonylureas such as glipizide and gliclazide push beta cells to release insulin regardless of glucose level. They work quickly and cost little.
  • Because the insulin release is not glucose-dependent, they can cause low blood sugar, particularly in older people, those skipping meals and those with kidney impairment.
  • They also tend to cause modest weight gain, and their effect wanes over the years as beta-cell function declines.
  • DPP-4 inhibitors slow the breakdown of natural GLP-1. They are well tolerated, weight-neutral and do not cause low blood sugar, but the glucose effect is modest and they do not reduce cardiovascular events.
  • Pioglitazone improves insulin sensitivity directly and has durable glucose effects, but causes fluid retention, weight gain and increased fracture risk, and is avoided in heart failure.
  • DPP-4 inhibitors and GLP-1 agonists are not used together, because they act on the same system.

Why it matters

Older does not mean obsolete. Cost, availability and individual circumstances mean these classes still have a place, as long as the trade-offs are explicit.

What's still uncertain

  • Whether sulfonylureas should still be used widely where newer drugs are affordable.
  • The role of pioglitazone in people with fatty liver disease.

Read more

Next: Insulin

Part 5 of 6

When it is needed

Review of many studies

What happens

Not a punishment and not a last resort.

What the research shows

  • Insulin is used when other medicines cannot achieve the target, when A1C is very high at diagnosis, during serious illness or hospital care, and in some kidney or liver disease where options are limited.
  • Treatment usually starts with a single long-acting dose, often at bedtime, with mealtime insulin added later if needed.
  • Insulin can cause low blood sugar, and anyone starting it needs to know the symptoms and how to treat them before the first dose.
  • Weight gain is common. Combining insulin with a GLP-1 agonist or SGLT2 inhibitor often reduces both the dose needed and the weight gain.
  • Doses are adjusted by pattern, not by single readings, and the adjustment is gradual.
  • Needing insulin reflects the natural decline in beta-cell function over years. It is often presented as a failure, and that framing delays treatment that would have helped.

Why it matters

Insulin is frequently started too late, because both clinicians and patients treat it as a defeat. The delay costs more than the injections do.

What's still uncertain

  • The best combination strategies to limit weight gain and hypoglycemia.
  • How to reduce the delay between need and initiation.

Read more

Next: Choosing

Part 6 of 6

How the decision is actually made

Review of many studies

What happens

The other conditions usually decide.

What the research shows

  • Established cardiovascular disease, heart failure or chronic kidney disease now steer the choice toward a GLP-1 agonist or SGLT2 inhibitor regardless of what A1C is doing.
  • Where weight is a major concern, a GLP-1 agonist is usually preferred.
  • Where cost is the dominant constraint, metformin and a sulfonylurea remain effective and inexpensive.
  • Where hypoglycemia must be avoided, such as in older adults living alone or people who drive for a living, classes that do not cause it are preferred.
  • Treatment is reviewed roughly every three to six months, and intensified if the target is not met.
  • Medicines should not be stopped because readings have improved; the improvement is usually because of them. Any reduction should be planned with a clinician, particularly after significant weight loss, when doses often do need to come down.

Why it matters

Modern diabetes treatment is chosen around the whole person, not around the glucose number alone. That is the main change of the last decade.

What's still uncertain

  • Whether early combination therapy beats stepwise escalation.
  • How to deprescribe safely after substantial weight loss.

Read more

More plain-language reading

See something wrong or unclear on this page? Suggest a correction. OwieClear is for education only and isn't medical advice.